NCT05504941 Detection of an Endovascular Treatment Target in Patients With an Acute, Spontaneous Intracerebral Hemorrhage
| NCT ID | NCT05504941 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Basel, Switzerland |
| Condition | Intracerebral Hemorrhage |
| Study Type | INTERVENTIONAL |
| Enrollment | 15 participants |
| Start Date | 2022-10-25 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 15 participants in total. It began in 2022-10-25 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is to determine if a treatment target for a potential endovascular therapy exists in patients with an acute, spontaneous (non-traumatic) ICH.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of an acute spontaneous ICH based on non-contrast CT * Time from symptom onset to anticipated start of cerebral DSA of under 3 hours * Agreement of the treating physician to perform DSA * Informed consent documented by signature or fulfilling the criteria for emergency consent procedures (deferral of consent) Exclusion Criteria: * High probability that the etiology of the bleeding is a ruptured aneurysm, an arteriovenous malformation or an amyloid angiopathy as judged by the treating physician * Any time critical surgical or minimal invasive intervention is planned * Evidence of an ongoing pregnancy, a negative pregnancy test is mandatory in all persons of childbearing potential * Contraindications against the use of iodine contrast media * Known severe kidney insufficiency (Glomerular filtration rate \< 30 ml/min)
Contact & Investigator
Marios-Nikos Psychogios, Prof Dr
STUDY DIRECTOR
Department of Neuroradiology, University Hospital Basel
Frequently Asked Questions
Who can join the NCT05504941 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Intracerebral Hemorrhage. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05504941 currently recruiting?
Yes, NCT05504941 is actively recruiting participants. Contact the research team at alex.brehm@usb.ch for enrollment information.
Where is the NCT05504941 trial being conducted?
This trial is being conducted at Basel, Switzerland.
Who is sponsoring the NCT05504941 clinical trial?
NCT05504941 is sponsored by University Hospital, Basel, Switzerland. The principal investigator is Marios-Nikos Psychogios, Prof Dr at Department of Neuroradiology, University Hospital Basel. The trial plans to enroll 15 participants.